Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021 by Mughal, TI, Psaila, B, DeAngelo, DJ, Saglio, G, Van Etten, RA, Radich, JP

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies by Mughal, TI, Pemmaraju, N, Psaila, B, Radich, J, Bose, P, Lion, T, Kiladjian, J-J, Rampal, R, Jain, T, Verstovsek, S, Yacoub, A, Cortes, JE, Mesa, R, Saglio, G, van Etten, RA

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. by Gambacorti-Passerini, C, Donadoni, C, Parmiani, A, Pirola, A, Redaelli, S, Signore, G, Piazza, V, Malcovati, L, Fontana, D, Spinelli, R, Magistroni, V, Gaipa, G, Peronaci, M, Morotti, A, Panuzzo, C, Saglio, G, Usala, E, Kim, D, Rea, D, Zervakis, K, Viniou, N, Symeonidis, A, Becker, H, Boultwood, J, Campiotti, L

The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative Eu... by Bonifazi, F, De Vivo, A, Rosti, G, Guilhot, F, Guilhot, J, Trabacchi, E, Hehlmann, R, Hochhaus, A, Shepherd, P, Steegmann, J, Kluin-Nelemans, H, Thaler, J, Simonsson, B, Louwagie, A, Reiffers, J, Mahon, F, Montefusco, E, Alimena, G, Hasford, J, Richards, S, Saglio, G, Testoni, N, Martinelli, G, Tura, S, Baccarani, M

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways by Magistroni, V, Mauri, M, D'Aliberti, D, Mezzatesta, C, Crespiatico, I, Nava, M, Fontana, D, Sharma, N, Parker, W, Schreiber, A, Yeung, D, Pirola, A, Redaelli, S, Massimino, L, Wang, P, Khandelwal, P, Citterio, S, Viltadi, M, Bombelli, S, Rigolio, R, Perego, R, Boultwood, J, Morotti, A, Saglio, G, Kim, D, Branford, S, Gambacorti-Passerini, C, Piazza, R